Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Javed Shaikh, Director of RWE & HEOR, Axtria, explains how harnessing next-generation sequencing and AI-powered analytics ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 7.31%, which has investors questioning if this is right time to ...

And our Fabry gene therapy study continues to generate best-in-class data, with a pivotal data readout expected in mid-2025.

Fabry Disease (isa-vec): The company plans to ... fitelparvovec): Developed in partnership with Pfizer (NYSE:PFE), this gene therapy candidate reported positive top-line data from the Phase ...

Sangamo has a clear regulatory pathway to accelerated approval for its Fabry disease gene therapy, potentially reducing approval time by three years. The company has significantly reduced its non ...

Chardan took over coverage of uniQure (QURE) with a Buy rating and price target of $38. The analyst, who cites the potential of the company’s ...

Orion Portfolio Solutions LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 8.6% ...